Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Medrxiv : the Preprint Server for Health Sciences|February 16, 2022
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
MMWR. Morbidity and Mortality Weekly Report|March 24, 2022
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022Mark W Tenforde, Wesley H Self, Manjusha Gaglani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2021
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024Kevin C Ma, Diya Surie, Adam S Lauring, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2024
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024Kevin C Ma, Diya Surie, Adam S Lauring, et al.
Open Forum Infectious Diseases|January 25, 2023
Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022Nathaniel M Lewis, Nancy Murray, Katherine Adams, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United StatesMark W Tenforde, Wesley H Self, Yuwei Zhu, et al.
MMWR. Morbidity and Mortality Weekly Report|February 29, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024Jennifer DeCuir, Amanda B Payne, Wesley H Self, et al.
MMWR. Morbidity and Mortality Weekly Report|September 23, 2021
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021Wesley H Self, Mark W Tenforde, Jillian P Rhoads, et al.
Pageof 11